MedTrace Logo

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03433027 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-04-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401) in patients with metastatic/recurrent HNSCC.

Conditions

Interventions

DRUG

BB-401

BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks

Sponsors & Collaborators

  • Benitec Biopharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2018-12-12
Completion
2020-04-06

Countries

  • Australia
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433027 on ClinicalTrials.gov